Multimodality Imaging Assessment of Sipuleucel T Treatment and in Vivo Immune Response of Metastatic Castration Resistant Prostate Cancer Patients
Phase of Trial: Phase II
Latest Information Update: 27 May 2019
Price : $35 *
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics
- 11 Dec 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 28 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Feb 2014 New trial record